Toxic Epidermal Necrolysis Caused by Eribulin

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Eribulin is a chemotherapy drug targeting microtubule structures to inhibit cancer cell proliferation.
• Toxic epidermal necrolysis (TEN) is a severe, life-threatening mucocutaneous reaction to medications.
• Angiosarcoma is a rare and aggressive cancer of the blood vessels.

Observation:

• A rare case of toxic epidermal necrolysis (TEN) was observed in a patient with angiosarcoma treated with eribulin.
• Severe mucosal and skin lesions developed after the third dose of eribulin, confirmed by biopsy.

Findings:

• The patient showed initial improvement with steroid therapy for toxic epidermal necrolysis.
• Recurrence of skin eruptions was noted upon continued eribulin administration.

Implications:

• This case underscores the need for investigating the immunological effects of eribulin.
• Further research is warranted on eribulin's potential role in severe drug eruptions and immune cell function.